Halozyme Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
Halozyme Therapeutics, Inc. income statement - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue1.020.830.660.440.270.200.15
Cost of Revenue0.160.270.210.120.040.050.01
Gross Profit0.860.560.450.330.220.150.14
Operating Expenses
Research & Development0.080.080.070.040.030.140.15
Selling, General & Administrative0.150.150.120.050.050.080.06
Operating Expenses0.300.220.160.050.080.220.21
Operating Income0.550.340.290.280.14-0.07-0.07
Other Income/Expense
Interest Income0.000.010.000.000.010.000.00
Interest Expense0.02-0.02-0.02-0.01-0.020.000.02
Other Income/Expense0.01-0.020.00-0.02-0.01-0.010.01
Income
Income Before Tax0.560.350.250.250.13-0.07-0.08
Income Tax Expense0.110.070.05-0.150.000.000.00
Net Income0.440.280.200.400.13-0.07-0.08
Net Income - Continuous Operations0.440.280.200.400.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA0.660.420.340.280.15-0.06-0.06
EBIT0.560.340.290.280.15-0.06-0.06
Depreciation & Amortization0.080.080.050.000.000.000.00
Earnings Per Share
Basic EPS4.002.001.003.001.00--1.00
Diluted EPS3.002.001.003.001.00--1.00
Basic Shares Outstanding0.130.130.140.140.140.290.14
Diluted Shares Outstanding0.130.130.140.150.140.140.14